Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorder Patients in Turkish Cohort Demographic, Clinical, and Laboratory Features

Basit Öğe Kaydı
dc.authoridAltintas, Ayse/0000-0002-8524-5087
dc.authoridDUMAN, Taskin/0000-0002-6552-4193
dc.authoridSoysal, Aysun/0000-0002-1598-5944
dc.authoridBoz, Cavit/0000-0003-0956-3304
dc.authoridMangan, Mehmet Serhat/0000-0001-7720-9003
dc.authoridSiva, Aksel/0000-0002-8340-6641
dc.contributor.authorAltintas, Ayse
dc.contributor.authorKarabudak, Rana
dc.contributor.authorBalci, Belgin P.
dc.contributor.authorTerzi, Murat
dc.contributor.authorSoysal, Aysun
dc.contributor.authorSaip, Sabahattin
dc.contributor.authorKurne, Asli Tuncer
dc.date.accessioned2024-09-18T20:52:43Z
dc.date.available2024-09-18T20:52:43Z
dc.date.issued2015
dc.departmentHatay Mustafa Kemal Üniversitesien_US
dc.description.abstractBackground: Neuromyelitis optica (NMO) is an immune-mediated, chronic relapsing, inflammatory disease characterized by severe attacks of optic neuritis and myelitis. Objective: To determine the demographic, clinical, and laboratory features; antibody status; and treatment modalities of patients with NMO and neuromyelitis optica spectrum disorders in a Turkish cohort from 11 centers. Methods: A total of 182 patients were included in this study. Data on age at disease onset, sex, type of attacks, clinical presentation, analysis of cerebrospinal fluid, serum antiaquaporin-4 antibody status, annual progression index, and medical and family histories were collected. Results: Mean age was 38.43 +/- 12.40 years (range, 13 to 75 y), and mean age at disease onset was 31.29 +/- 12.40 years (median, 29 y; range, 10 to 74 y). In NMO group, the rate of NMO immunoglobulin (Ig)G positivity was 62.5%. The annual progression index was significantly higher in the longitudinally extending spinal cord lesion. The mean Expanded Disability Status Scale score was higher in the late than early-onset NMO group. Conclusion: Our results revealed a lower rate of NMO IgG positivity, more severe disability in patients with NMO/neuromyelitis optica spectrum disorders presenting with either transverse myelitis or late-onset NMO, and no correlation between disability and NMO IgG status.en_US
dc.identifier.doi10.1097/NRL.0000000000000057
dc.identifier.endpage66en_US
dc.identifier.issn1074-7931
dc.identifier.issue4en_US
dc.identifier.pmid26468870en_US
dc.identifier.scopus2-s2.0-84945182146en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage61en_US
dc.identifier.urihttps://doi.org/10.1097/NRL.0000000000000057
dc.identifier.urihttps://hdl.handle.net/20.500.12483/11341
dc.identifier.volume20en_US
dc.identifier.wosWOS:000369951300002en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherLippincott Williams & Wilkinsen_US
dc.relation.ispartofNeurologisten_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectneuromyelitis opticaen_US
dc.subjectneuromyelitis optica spectrum disorderen_US
dc.subjectaquaporin-4 antibodyen_US
dc.subjectlate onseten_US
dc.subjectprognosisen_US
dc.subjectclinical findingsen_US
dc.titleNeuromyelitis Optica and Neuromyelitis Optica Spectrum Disorder Patients in Turkish Cohort Demographic, Clinical, and Laboratory Featuresen_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
[ N/A ]
İsim:
Tam Metin / Full Text
Boyut:
126.1 KB
Biçim:
Adobe Portable Document Format
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu